HSE to consider access to weight loss drug Mounjaro
Summary
Newstalk Breakfast discusses the HSE’s potential reimbursement of Monjaro, a GLP-1 weight loss drug. Dr. Michael Crotty, Clinical Lead for Obesity at the Irish College of GPs, argues that treating obesity as a chronic disease could save costs by preventing expensive complications like diabetes and cardiovascular issues. However, he notes that universal access would be financially unsustainable, suggesting a phased approach prioritizing those with severe obesity and established health complications. The segment highlights the need for long-term management and support services, as these medic…
Topics discussed
Intro: HSE to consider subsidizing Monjaro
Cost of treating obesity complications vs medication
Shifting focus from aesthetics to chronic disease
Defining obesity and eligibility thresholds
Phased approach and restricted reimbursement models
Early intervention and pre-obesity concepts
Holistic treatment and support for GPs
Health benefits and finite resource constraints
Balancing health priorities with state costs
Long-term management of chronic obesity
Listen ad-free on Castria